At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 82 enrolled
Drug / intervention
Melatonin +1 moredrug
Likely dose
Melatonin 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Clinical Trial of Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients
In Brief
A Phase 3 clinical trial evaluating Melatonin and Placebo for Gastrointestinal Cancer and Lung Cancer. Completed, enrolled 82 participants across 2 sites.
Detailed Summary
The goal of this clinical research study is to evaluate the effectiveness of melatonin for the management of poor appetite and weight loss in advanced cancer patients. The effectiveness of melatonin on weight gain, keeping/gaining of lean muscle mass, improved appetite, and side effects will also be evaluated.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastrointestinal Cancer, Lung Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2006
First PostedAug 2007
Primary CompletionDec 2012
TodayJul 2026
First PostedAug 8, 2007
Enrollment StartJun 1, 2006
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 18.9 years ago
Interventions
Melatonindrug
20 mg by mouth daily for 4 Weeks
Placebodrug
Capsule by mouth daily for 4 Weeks